



Appendix 3

**This appendix was part of the submitted manuscript and has been peer reviewed.
It is posted as supplied by the authors.**

Appendix to: Broadley SA, Barnett MH, Boggild M, et al. A new era in the treatment of multiple sclerosis. *Med J Aust* 2015; 203: 139-141. doi: 10.5694/mja14.01218.

Appendix 3: Competing interests statement for Broadley SA et al, A new era in the treatment of multiple sclerosis.

Simon A. Broadley has received honoraria for attendance at advisory boards and travel sponsorship from Bayer-Schering, Biogen Idec, Merck Serono, Novartis, and Sanofi-Genzyme; speaker honoraria from Biogen Idec, Genzyme and Novartis; he is an investigator in clinical trials sponsored by Biogen Idec, Novartis and Genzyme, and was the recipient of an unencumbered research grant from Biogen Idec.

Michael H. Barnett has received honoraria for his participation in advisory boards, and travel sponsorship from Novartis, BioCSL, Genzyme and Biogen Idec.

Bruce J Brew has received honoraria as a board member from GlaxoSmithKline, Biogen Idec, ViiV Healthcare and Merck Serono; speaker honoraria from ViiV Healthcare, Boehringer Ingelheim, Abbott, Abbvie, and Biogen Idec; travel sponsorship from Abbott and Viiv Healthcare; and research support funding from Eli Lilly, GlaxoSmithKline, ViiV Healthcare and Merck Serono.

Helmut Butzkueven has received honoraria for serving on scientific advisory boards for Biogen Idec, Novartis and Sanofi-Genzyme; conference travel sponsorship from Novartis and Biogen Idec; and honoraria for speaking and acting as Chair at educational events organised by Novartis, Biogen Idec, Medscape and Merck Serono; serves on steering committees for trials conducted by Biogen Idec and Novartis; is chair (honorary) of the MSBase Foundation, which has received research support from Merck Serono, Novartis, Biogen Idec, Genzyme-Sanofi and CSL Biopharma, and has received research support from Merck Serono.

Robert Heard has received honoraria, educational support and clinical funding from Novartis, Biogen Idec, Genzyme and bioCSL.

Allan G. Kermode has received scientific consulting fees and lecture honoraria from Bayer, bioCSL, Biogen Idec, Genzyme, Merck, Novartis, Sanofi-Aventis, and Teva.

Jeannette Lechner-Scott has received unencumbered funding and honoraria for presentations and membership of advisory boards from Sanofi Aventis, Biogen Idec, Bayer Health Care, CSL, Genzyme, Merck Serono and Novartis Australia.

Richard A. L. Macdonell has received honoraria for attendance at advisory boards and travel sponsorship from Bayer-Schering, Biogen Idec, CSL, Merck Serono, Novartis and Sanofi-Genzyme.

Mark Marriott has received travel sponsorship, honoraria, trial payments, research and clinical support from Bayer Schering, Biogen Idec, bioCSL, Genzyme, Novartis and Sanofi Aventis Genzyme.

Deborah F. Mason has received honoraria for attendance at advisory boards from Biogen Idec, and travel sponsorship from Bayer-Schering, Biogen Idec and Sanofi-Genzyme.

Stephen W. Reddel has received travel sponsorship, honoraria, trial payments, research and clinical support from Aspreva, Baxter, Bayer-Schering, Biogen Idec, bioCSL, Genzyme, Novartis, Sanofi-Aventis, Genzyme and Servier.

Cameron P. Shaw has received travel sponsorship from Biogen Idec, Novartis and Bayer-Schering.

Mark Slee has received research support from Novartis, Biogen Idec and bioCSL.

Judith M. Spies has received honoraria for lectures and participation in advisory boards; and travel sponsorship from Novartis, bioCSL, Genzyme and Biogen Idec.

Bruce V. Taylor has received travel sponsorship from Novartis and Bayer Schering.

William M. Carroll has been the recipient of travel sponsorship from, and provided advice to, Bayer-Schering Pharma, Biogen Idec, Novartis, Genzyme, Sanofi-Aventis, bioCSL and Merck Serono.

Trevor J. Kilpatrick has received travel sponsorship from Novartis, bioCSL, Merck Serono and Biogen Idec; speaker honoraria from Biogen Idec, BioCSL, Merck Serono and Novartis; research support from Biogen Idec, GlaxoSmithKline, Bayer-Schering and Merck Serono; and scientific consulting fees from GlaxoSmithKline China, Biogen Idec and Novartis.

John King has received remuneration for advisory board activities and presentations from Bayer Healthcare, Biogen Idec, bioCSL, Genzyme and Novartis.

Pamela A. McCombe has received honoraria or travel sponsorship from Novartis, Sanofi-Aventis and Biogen Idec.

John D. Pollard has received honoraria for participation in advisory boards and travel sponsorship from Bayer-Schering, Biogen Idec, Novartis and Sanofi- Aventis, and was the recipient of unencumbered research grants from Biogen Idec and Bayer-Schering.

Ernest Willoughby has received honoraria for participation in advisory boards from Biogen Idec and Novartis; travel sponsorship from Biogen Idec, Bayer-Schering and Teva; and is an investigator in clinical trials funded by Biogen Idec and Teva.